Blockchain Registration Transaction Record

ABVC Secures $70K Payment for Revolutionary Eye Treatment Vitargus

ABVC BioPharma receives $70K licensing payment from ForSeeCon for Vitargus®, the world's first biodegradable vitreous substitute. Learn about this breakthrough in retinal surgery technology.

This development matters because Vitargus® represents a potential breakthrough in retinal surgery that could eliminate the uncomfortable face-down recovery period currently required for millions of patients worldwide. The successful commercialization of this biodegradable vitreous substitute could transform post-operative care for retinal detachment and other vitreoretinal conditions, significantly improving patient quality of life during recovery. Additionally, the growing US$2.5 billion global market for vitreous substitutes indicates substantial commercial potential, while ABVC's strategic partnerships and GMP facility development demonstrate progress toward making this innovative treatment available to patients who currently face challenging recovery protocols after eye surgery.